Item

Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis

Van Cutsem, E.
; 
Xu, J.
; 
Raymond, E.
; 
Hubner, R.
; 
Yoon, H.
; 
Kato, K.
; 
Wyrwicz, L. S.
; 
Tougeron, D.
; 
Park, S. R.
; 
Fonseca, P. J.
... show 9 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Authors
Van Cutsem, E.
Xu, J.
Raymond, E.
Hubner, R.
Yoon, H.
Kato, K.
Wyrwicz, L. S.
Tougeron, D.
Park, S. R.
Fonseca, P. J.
Kojima, T.
Ishihara, R.
Avallone, A.
Cid, R. A. P.
Xu, S.
Yan, S.
Shi, J.
Kong, X.
Lordick, F.
Affiliation
UZ Leuven Univ Hosp Leuven Campus Gasthuisberg, Digest Oncol Dept, Leuven, Belgium Fifth Med Ctr Chinese PLA Gen Hosp, Chinese PLA Hosp South Campus 307, Gastrointestinal Dept, Beijing, Peoples R China Hop St Joseph Grp Hosp Paris St Joseph, Med Oncol, Paris, France Christie NHS Fdn Trust, Med Oncol, Manchester, England Mayo Clin, Oncol, Rochester, MN USA Natl Canc Ctr Tsukiji Campus, Dept Gastrointestinal Med Oncol, Chuo Ku, Tokyo, Japan Mar Sklo dowska Curie Natl Res Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland CHU Poitiers Jean Bernard Hop, Gastroentrol, Poitiers, France Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea Hosp Univ Cent Asturias, Oncol, Oviedo, Spain Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan Osaka Int Canc Inst, Gastroenterol, OICI, Osaka, Japan Ist Nazl Tumori IRCCS Fdn G Pascale, Med Oncol, Naples, Italy Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain BeOne Med Shanghai Co Ltd, Global Stat, Shanghai, Peoples R China BeOne Med Beijing Co Ltd, Clin Dev, Beijing, Peoples R China BeOne Med Beijing Co Ltd, Clin Biomarker, Beijing, Peoples R China BeOne Med Shanghai Co Ltd, Clin Dev, Shanghai, Peoples R China Universitares Krebszentrum Leipzig, Dept Med, Univ Klinikum Leipzig, Leipzig, Germany
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Van Cutsem E, Xu J, Raymond E, Hubner R, Yoon H, Kato K, et al. Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis. ANNALS OF ONCOLOGY. 2025 JUL;36. PubMed PMID: WOS:001545624000061. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/628198
Embedded videos